VT-20101 - Phase 1b Study of VERVE-201 in Patients with Refractory Hyperlipidemia
Research type
Research Study
Full title
A Phase 1b Single Ascending Dose Study to Evaluate the Safety of VERVE-201 in Patients with Refractory Hyperlipidemia
IRAS ID
1010047
Contact name
Matthew Schmidt
Contact email
Sponsor organisation
Verve Therapeutics, Inc.
Clinicaltrials.gov Identifier
Research summary
Verve Therapeutics is funding this research to see if VERVE-201 can safely lower cholesterol in patients who have not been able to achieve their recommended cholesterol goal. High cholesterol occurs when high levels of a type of fat called low-density lipoprotein cholesterol (LDL-C), sometimes referred to as “bad” cholesterol, circulate in the blood. If there is too much LDL-C in your blood, it could cause your arteries to narrow and increase the risk of suffering a heart attack or stroke. VERVE-201 is designed to lower the levels of LDL-C in the blood. VERVE-201 does this by making a change to the DNA in a gene called “ANGPTL3” to turn the gene off. Turning off the ANGPTL3 gene is known to lower LDL-C levels. VERVE-201 is an investigational medicine not yet approved for use by any health authorities. This is the first time VERVE-201 is being tested in humans. The primary goal of this study is to determine whether VERVE-201 is safe. Participants will be in the study for approximately one year but will be asked to participate in a long-term follow-up study for up to 15 years.
REC name
North East - York Research Ethics Committee
REC reference
24/NE/0119
Date of REC Opinion
20 Aug 2024
REC opinion
Further Information Favourable Opinion